WilmerHale has one of the leading antitrust and competition practices in the United States and Europe, as consistently recognized by publications such as Chambers and Global Competition Review. With more than 70 competition lawyers in the United States, Europe and China, we are able to advise healthcare providers and payers on the full spectrum of antitrust issues in the jurisdictions where they do business. We regularly counsel on the issues associated with a company’s operational activities; we have secured antitrust clearance for hundreds of complex mergers and joint ventures; and we have won numerous victories for clients in private and government litigation.


We have compiled a remarkable record of resolving antitrust claims through summary disposition, at trial and on appeal. Some of our recent successes in the healthcare sector include:

  • Defending Cephalon in multiple antitrust lawsuits and a related FTC investigation challenging patent litigation settlements between the company and four other companies seeking FDA approval to market generic versions of Cephalon’s leading pharmaceutical product, Provigil
  • Representing a major insurance carrier in the Insurance Brokerage Antitrust Litigation, where we were successful in securing dismissal of all federal antitrust, RICO and ERISA claims in the consolidated class action complaint against employee benefits insurers, as well as the related state law claims

In addition, we have extensive experience in securing merger clearance for companies in a wide range of industries, including healthcare. The mergers for which we have secured clearance in the healthcare sector include:

  • Representing the second largest provider of regulated medical waste services in obtaining clearance for its acquisition by the largest provider of those services
  • Obtaining FTC clearance for Millennium Pharmaceuticals in connection with its $8.8 billion sale to Takeda—the largest overseas acquisition by a Japanese drug firm

Publications & News


May 20, 2014

Ophthotech Corporation Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis

On May 19, 2014, WilmerHale client Ophthotech Corporation announced that the company had entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD).

March 18, 2010

Chambers USA 2010 Honors WilmerHale, Ranking Over 100 Lawyers and Dozens of Practices

One-hundred and two WilmerHale lawyers will be recognized in the eighth edition of Chambers USA: America's Leading Lawyers for Business.


March 27, 2010

Special Olympics Massachusetts: Bio-Ball 2010

Cambridge, Massachusetts